COMBINATION OF CD37 ANTIBODIES WITH BENDAMUSTINE

摘要

The present invention relates to immunotherapies that are based on depletion of CD37-positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/patient using a combination of CD37 antibody/antibodies and bendamustine. The combination of CD37 antibodies and bendamustine is shown to have a synergistic effect. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity.

主权项

1. A method of using a CD37 antibody in combination with bendamustine for the treatment of a patient suffering from a CD37-positive malignancy, whereby the CD37 antibody comprises:
a variable heavy chain comprising CDRs having the SEQ ID NOs: 15, 16 or 21, and 17, and a variable light chain comprising CDRs having the SEQ ID NOs: 18, 19 and 20.